Dramatic changes in muscle contractile and structural properties after 2 botulinum toxin injections
ABSTRACT Introduction: Botulinum toxin is frequently administered serially to maintain therapeutic muscle paralysis, but the effect of repeated doses on muscle function are largely unknown. This study characterized the muscle response to 2 onabotulinum toxin (BoNT) injections separated by 3 months....
Saved in:
Published in | Muscle & nerve Vol. 52; no. 4; pp. 649 - 657 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.10.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | ABSTRACT
Introduction: Botulinum toxin is frequently administered serially to maintain therapeutic muscle paralysis, but the effect of repeated doses on muscle function are largely unknown. This study characterized the muscle response to 2 onabotulinum toxin (BoNT) injections separated by 3 months. Methods: Animal subjects received a single toxin injection (n = 8), 2 BoNT injections separated by 3 months (n = 14), or 1 BoNT and 1 saline injection separated by 3 months (n = 8). Results: The functional effect of 2 serial injections was exponentially greater than the effect of a single injection. While both groups treated with a single BoNT injection had decreased torque in the injected leg by approximately 50% relative to contralateral legs, the double BoNT injected group had decreased torque by over 95% relative to the preinjection level. Both single and double BoNT injections produced clear signs of fiber‐type grouping. Conclusions: These experiments demonstrate a disproportionately greater effect of repeated BoNT injections. Muscle Nerve 52: 649–657, 2015 |
---|---|
Bibliography: | Allergan, Inc. ArticleID:MUS24576 istex:242842B8D85F39BE4736C37355D2D007E2A4B30A Department of Veterans AffairsNIH - No. RX000670; No. R24HD050837; No. AR057013 ark:/67375/WNG-QVJ006RZ-F Funding for this study was provided by the Department of Veterans Affairs (grant RX000670), NIH (grants R24HD050837 and AR057013), and Allergan, Inc. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0148-639X 1097-4598 1097-4598 |
DOI: | 10.1002/mus.24576 |